Lifespan.io – Join Us: Become a Lifespan Hero!
We are building public awareness and access to innovative treatments for controlling aging and age-related diseases!
- 48% Funded
- $2,448 per month
Related Organizations
Campaign List
Introducing the Public Longevity Group: Building the Future of Public Trust
Building the first public sentiment analysis engine to unlock public trust in longevity.
- 104% Funded
- $104,395 Funded
- campaign
complete
Pearl: Participatory Evaluation of Aging with Rapamycin for Longevity
The first large-scale placebo-controlled clinical trial to determine the effects of Rapamycin on human longevity.
- 243% Funded
- $182,838 Funded
- campaign
complete
MitoMouse: SENS Transgenic Mouse Project
Creating a transgenic mouse demonstrating the rescue of Mitochondrial DNA mutations in mammals. We will express the mitochondrial ATP8 gene from the nucleus as...
- 155% Funded
- $77,625 Funded
- campaign
complete
Can NMN Increase Longevity?
The first long-term lifespan study in mice involving supplementation with NMN, a precursor of NAD+ metabolism, which has been shown to reduce aging markers and...
- 250% Funded
- $75,285 Funded
- campaign
complete
MouseAge: Visual Biomarker for Mouse Aging
Using AI and Computer Vision Techniques to Determine Age and Assess the Effect of Therapies Against Aging in Mice, Increasing the Pace of Research.
- 130% Funded
- $19,508 Funded
- campaign
complete
AgeMeter: Functional Age Biomarkers
Developing a diagnostic system to measure human functional age in comparison to chronological age, and assist in the assessment of anti-aging therapeutics.
- 100% Funded
- $30,061 Funded
- campaign
complete
CellAge: Targeting Senescent Cells With Synthetic Biology
Designing better systems for detection and safe removal of dysfunctional “senescent” cells to improve health and treat age-related diseases.
- 171% Funded
- $34,215 Funded
- campaign
complete
OncoSENS Control ALT Delete Cancer
High-throughput screening of a library of diverse drugs to find treatments for ‘ALT’ cancers, those which rely on Alternative Lengthening of Telomeres.
- 120% Funded
- $72,002 Funded
- campaign
complete
The Major Mouse Testing Program
Testing a new class of compounds, Senolytics, on their ability to extend healthy lifespan by clearing out dysfunctional cells in the body.
- 115% Funded
- $52,075 Funded
- campaign
complete
Articles from this author
October 06, 2026
A new study links an age-related decline in cellular maintenance to impaired immune clearance. Activating the pathway reduced signs of senescence in aged mice [1]. Senescence and autophagy Cellular senescence, which occurs when cells stop dividing and start emitting largely pro-inflammatory stress signals, the senescence-associated secretory phenotype (SASP), is a double-edged sword. On the one...
October 05, 2026
Researchers have discovered key biomarkers that are strongly linked to all-cause mortality and identified four measurements with independent predictive power. Biological versus chronological This paper opens with a discussion of a familiar fact for people interested in living longer: one's biological age is not the same as one's chronological age [1]. Biological age gives a...
October 02, 2026
At a panel in Boston, senior officials announced plans to include aging in the agency’s regulatory science agenda and discussed how therapies could move toward approval. Longevity has a partner The 2026 edition of the Aging Research and Drug Discovery Meeting (ARDD) kicked off yesterday. This is one of the biggest and longest-running longevity conferences,...
October 01, 2026
The Biomarkers of Aging Consortium will host its fourth annual Biomarkers of Aging Conference on October 5 and 6, 2026, at the Joseph B. Martin Conference Center at Harvard Medical School. The meeting brings together academic, clinical, industry, regulatory, and philanthropic leaders working to develop, validate, and apply biomarkers of aging. Therapies that target aging...
October 01, 2026
Which generation will be considered "the last to die" of age-related diseases is ultimately a question of technological development and deployment. Here's what's been done on that front in September. Interviews The Last Generation to Die: Interview With Tim Maupin: Filmmaker Tim Maupin has spent a number of years developing The Last Generation to Die,...
September 29, 2026
A new preprint study suggests that transplanted hearts’ epigenetic age and possibly function are influenced by their recipients’ age. The findings can be relevant to both expanding the donor pool and rejuvenation through organ replacement [1]. The heart of the matter Over the last few decades, organ transplantation has revolutionized treatment of multiple conditions. It...